StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1737.TW$31.70+0.32%
Fair $31.70+0.0%

1737.TW

Taiyen Biotech Co., Ltd.

Consumer Defensive / Household & Personal ProductsTaiwan

$31.70

+0.10 (+0.32%)

Fairly Valued+0.0%Fair Value $31.70Fund rank 33/100 · Data gapFallback financials|
SA 41/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $130.3M · quality 68.7/100

Data gap 33/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 57/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

41/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists.
Thesis & Journal · 1737.TWLocal privado en este navegador · Taiyen Biotech Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$6.3B

P/E

15.9x

↑

EV/EBITDA

7.0x

↓

ROE

5.9%

↓

Gross Margin

40.6%

↑

Debt/Equity

0.03

↓
52-Week Range$32
$31$33

TradingView lightweight chart

1737.TW price, volumen y niveles de valoración

Último $31.70Periodo +23.2%
Fair value: $31.70

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-2.9%

FCF CAGR

-26.9%

FCF margin

3.9%

FCF / Net income

0.33x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.31B · net income $399.9M · FCF $130.3M

2022-FY → 2025-FY

Gross margin

40.6%+5.3% pts

Operating margin

14.1%+1.8% pts

Net margin

12.1%+0.3% pts

FCF margin

3.9%-5.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$3.31B$3.31B$3.24B$3.41B$3.61B
Net Income$399.9M$399.9M$371.5M$300.4M$426.7M
EBITDA$743.3M$743.3M$658.0M$530.5M$730.1M
EPS——1.851.502.13
Gross Margin40.6%40.6%40.8%36.9%35.3%
Operating Margin14.1%14.1%13.3%11.6%12.3%
Net Margin12.1%12.1%11.5%8.8%11.8%
Balance Sheet
Debt/Equity0.030.030.050.050.04
Current Ratio3.253.25———
Cash Flow
Free Cash Flow$130.3M$130.3M$352.5M$109.4M$334.1M
Returns
ROE5.9%5.9%5.6%4.6%6.5%
Valuation
P/E15.9315.9317.3822.8315.19
EV/EBITDA7.017.017.9210.827.14
P/B0.930.930.971.060.99
Growth & Yield
Revenue Growth2.1%2.1%-5.0%-5.7%—
EPS Growth——23.3%-29.6%—
Dividend Yield4.1%4.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +0.6%

Total return

+0.6%

Start / end P/E

n/dx → n/dx

EPS bridge

1.85 → n/d

Residual

-3.5%

EPS growthn/d
Multiple reratingn/d
Dividend+4.1%
Residual / FX / buybacks / cross-term-3.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.